IP Library Granted Patent US 9,423,372
Granted Patent B2
US 9,423,372 · App. 14/222,075 · Granted Aug 23, 2016

Measurement and uses of oxidative status

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,423,372
App. No.
14/222,075
Granted
Aug 23, 2016
Kind
B2
Abstract

The present invention provides a method of determining the overall oxidative status of a body fluid or a tissue of a patient by measuring the oxidation-reduction potential (ORP) of the body fluid or tissue. The method has been found to be useful in the diagnosis, evaluation and monitoring of patients who have suffered a trauma (such as a head injury), patients suspected of being critically-ill or who are critically ill, patients who have an infection, and patients suspected of having a myocardial infarction (MI) or who have had an MI. The method has also been found useful in monitoring and evaluating exercise performance in patients. In addition, the method has been found useful in monitoring and evaluating stored blood products and patients who will receive such a product.

Claims (10)

1. A method for determining the efficacy of a treatment for cardiovascular disease in a patient having a cardiovascular disease, wherein the oxidation-reduction potential (ORP) of a sample from the patient is higher than normals, the method comprising:

a. administering the treatment for cardiovascular disease to the patient;

b. following administration of the treatment, measuring the oxidation-reduction potential (ORP) of a body fluid and/or a tissue from the patient, by contacting an electrode with the body fluid or tissue of the patient, wherein the electrode is connected to a meter that provides a readout of the ORP; and

c. determining if the ORP value of the body fluid and /or tissue from the patient is significantly different than an ORP value obtained prior to the treatment;

wherein if the post-treatment ORP value is lower than the pre-treatment ORP value, maintaining the treatment; and wherein if the post-treatment ORP value is the same as, or greater than, the pre-treatment ORP value, administering a more aggressive, additional or different treatment to the patient.

2. The method of claim 1 wherein the ORP measurement is used in combination with other patient information to determine if the treatment should be maintained or if the patient should be administered a more aggressive, additional or different treatment.

3. The method of claim 1 wherein the sample is a body fluid selected from the group consisting of blood, plasma or serum.

4. The method of claim 1 , wherein the ORP is measured once per day or a plurality of times per day.

5. The method of claim 1 , wherein the cardiovascular disease is selected from the group consisting of myocardial infarction, acute coronary syndrome, artherosclerosis, heart failure, high blood pressure, stroke, transient ischemic attack, impaired circulation, heart disease, cholesterol and plaque formation, ischemia, ischemia reperfusion injury, peripheral vascular disease, myocardial infection, and kidney failure.

6. The method of claim 1 , wherein the cardiovascular disease is heart failure.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 6, 2021
From: AYTU BIOSCIENCE, INC.
To: CAERUS BIOTECHNOLOGIES
Reel/Frame 057716/0502 →
MERGER Recorded Aug 20, 2015
From: LUOXIS DIAGNOSTICS, INC.
To: ROSEWIND CORPORATION
Reel/Frame 036380/0283 →
CERTIFICATES OF CONVERSION AND INCORPORATION Recorded Aug 20, 2015
From: ROSEWIND CORPORATION
To: AYTU BIOSCIENCE, INC.
Reel/Frame 036400/0479 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2014
From: BAR-OR, DAVID; BAR-OR, RAPHAEL
To: LUOXIS DIAGNOSTICS, INC.
Reel/Frame 033111/0849 →